As of Jun 30, 2026, Myriad Genetics, Inc. had total assets of $638.9 million and total liabilities of $335.0 million. Total assets were down 5.7% from a year earlier. Stockholders' equity was $303.9 million. It held $115.2 million in cash and investments against $210.5 million of total debt, net debt of $95.3 million. The current ratio, current assets divided by current liabilities, was 2.21.
USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.
| Line |
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash |
115
+54.8%
|
124
+35.5%
|
150
+46.1%
|
145
+45.5%
|
74
-19.5%
|
92
-5.3%
|
102
-22.5%
|
100
+31.4%
|
| Short-term investments |
—
|
—
|
—
|
—
|
—
|
—
|
0
-100.0%
|
0
-100.0%
|
| Cash and investments |
115
+54.8%
|
124
+35.5%
|
150
+46.1%
|
145
+45.5%
|
74
-23.5%
|
92
-12.0%
|
102
-27.3%
|
100
+15.8%
|
| Receivables |
110
-20.1%
|
124
+2.8%
|
115
-4.9%
|
118
-6.1%
|
137
+16.3%
|
120
+1.9%
|
121
+6.0%
|
126
+9.1%
|
| Inventory |
31
+6.6%
|
28
-1.4%
|
31
+11.3%
|
32
+20.6%
|
29
+10.0%
|
28
+15.0%
|
28
+25.0%
|
26
+4.4%
|
| Total current assets |
289
+1.7%
|
313
+8.9%
|
333
+11.6%
|
345
+17.6%
|
284
-2.5%
|
287
-1.1%
|
298
-5.0%
|
293
+10.5%
|
| Property and equipment, net |
109
-3.6%
|
112
-2.2%
|
114
-2.9%
|
111
-3.5%
|
113
-2.8%
|
114
-3.8%
|
117
-1.3%
|
115
-4.4%
|
| Goodwill |
47
-8.7%
|
47
-83.5%
|
52
-82.0%
|
52
-82.0%
|
52
-82.0%
|
286
-0.2%
|
286
-0.4%
|
286
-0.1%
|
| Total assets |
639
-5.7%
|
674
-33.0%
|
707
-31.2%
|
728
-32.7%
|
677
-37.6%
|
1,006
-9.4%
|
1,028
-10.4%
|
1,081
-5.9%
|
| Liabilities and equity | ||||||||
| Accounts payable |
30
-1.6%
|
33
+16.0%
|
30
-7.1%
|
32
+7.4%
|
31
-7.2%
|
28
-15.1%
|
32
+25.2%
|
30
-12.7%
|
| Total current liabilities |
131
-34.6%
|
130
-13.8%
|
134
-18.5%
|
148
-4.1%
|
200
+34.3%
|
151
+3.4%
|
164
+5.3%
|
154
-26.3%
|
| Total liabilities |
335
+15.8%
|
336
+11.7%
|
339
+3.7%
|
355
+1.6%
|
289
-16.1%
|
301
-14.1%
|
326
-10.1%
|
350
-24.9%
|
| Stockholders' equity |
304
-21.7%
|
337
-52.1%
|
368
-47.5%
|
373
-49.1%
|
388
-47.6%
|
705
-7.2%
|
701
-10.5%
|
732
+7.1%
|
| Debt | ||||||||
| Debt due within a year |
—
|
—
|
—
|
—
|
59
|
—
|
—
|
—
|
| Long-term debt |
121
|
120
+102.9%
|
120
+202.8%
|
120
+206.4%
|
0
-100.0%
|
59
+53.2%
|
40
+2.9%
|
39
+1.3%
|
| Lease liabilities |
90
-5.7%
|
91
-7.2%
|
90
-10.7%
|
93
-10.9%
|
95
-8.9%
|
98
-9.1%
|
101
-11.4%
|
104
-36.1%
|
| Total debt |
210
+36.2%
|
212
+34.2%
|
210
+49.5%
|
212
+48.4%
|
155
+7.9%
|
158
+7.4%
|
140
-7.8%
|
143
-28.9%
|
| Net cash |
-95
-18.8%
|
-87
-32.4%
|
-60
-58.8%
|
-67
-54.9%
|
-80
-74.3%
|
-66
-54.8%
|
-38
-238.4%
|
-43
+62.5%
|
| Ratios | ||||||||
| Current ratio |
2.21x
|
2.40x
|
2.49x
|
2.33x
|
1.42x
|
1.90x
|
1.82x
|
1.90x
|
| Debt to equity |
0.69x
|
0.63x
|
0.57x
|
0.57x
|
0.40x
|
0.22x
|
0.20x
|
0.20x
|
| Return on equity |
-37.05%
|
-118.52%
|
-99.43%
|
-107.43%
|
-101.83%
|
-14.39%
|
-18.16%
|
-15.85%
|
| Return on assets |
-17.62%
|
-59.36%
|
-51.78%
|
-55.01%
|
-58.35%
|
-10.08%
|
-12.39%
|
-10.73%
|
| Book value per share |
3.18
|
3.57
|
3.94
|
4.00
|
4.17
|
7.65
|
7.68
|
8.04
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- MYGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 899923
- Former names
- MYRIAD GENETICS INC (until Nov 5, 2026)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.